Versican G3 modulated breast cancer cell apoptosis induced by chemotherapeutic drugs through activation of EGFR related signaling.

a) 1×104 G3- and vector-transfected MT-1, MDA-MB-468, 66c14, 4T07, and 4T1 cells were inoculated and cultured in 10% FBS/DMEM medium in 96 well culture dishes for 12 hours. After cell attachment, cells were treated with 2 µM Docetaxel for 24 hours. Cell viability was tested by WST-1 assays. b) All cells were treated with 8 µM Doxorubicin, and subjected to WST-1 assays. c) All cells were treated with 10 µM Epirubicin, and subjected to WST-1 assays. Compared with vector control group, n = 6, * p<0.05, **p<0.01, analyzed with t-test. d) Treated with 40 µM C2-ceramide, 2 µM Docetaxel, 8 µM Doxorubicin, 10 µM Epirubicin, 15 mM Cyclophosphamide, or 30 µM Trastuzumab for 6 hours, G3-expressing and vector- expressing 66c14 cells were processed to lysates and subjected to immunoblotting with antibodies to pSAPK/JNK, SAPK/JNK, ERK2, pERK, and β-actin. e) G3-transfected and vector-transfected 66c14 cells (1×104) were inoculated and cultured in 10% FBS/DMEM medium in 96 well culture dishes for 12 hours. After cell attachment, we added Docetaxel (2 µM), and EGF (20 ng/ml), AG 1478 (2.0 µM), PD 98059 (50 µM), or SP 600125 (100 nM) cultured for 24 hours. WST-1 Cell Survival Assays were used to analyze cell viability. f) G3-transfected and vector-transfected 66c14 cells (1×104) were also treated with Doxorubicin (8 µM), and EGF (20 ng/ml), AG 1478 (2.0 µM), PD 98059 (50 µM), or SP 600125 (100 nM) cultured for 24 hours. Cell viability was analyzed by WST-1 assays. Compared with vector control group, n = 8, * p<0.05, **p<0.01, analyzed with t-test.